Vivelle-Dot

See also: Generic Vivelle

Vivelle-Dot is a brand name of estradiol, approved by the FDA in the following formulation(s):

VIVELLE-DOT (estradiol - film, extended release; transdermal)

• 
  Manufacturer: NOVARTIS
  
  Approval date: January 8, 1999
  
  Strength(s): 0.05MG/24HR ^[AB1], 0.1MG/24HR ^[RLD][AB1]

Has a generic version of Vivelle-Dot been approved?

No. There is currently no therapeutically equivalent version of Vivelle-Dot available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vivelle-Dot. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Solubility parameter based drug delivery system and method for altering drug saturation concentration
  Patent 5,474,783
  Issued: December 12, 1995
  Inventor(s): Miranda; Jesus & Sablotsky; Steven
  Assignee(s): Noven Pharmaceuticals, Inc.
  The method of adjusting the saturation concentration of a drug in a transdermal composition for application to the dermis, which comprises mixing polymers having differing solubility parameters, so as to modulate the delivery of the drug. This results in the ability to achieve a predetermined permeation rate of the drug into and through the dermis. In one embodiment, a dermal composition of the present invention comprises a drug, an acrylate polymer, and a polysiloxane. The dermal compositions can be produced by a variety of methods known in the preparation of drug-containing adhesive preparations, including the mixing of the polymers, drug, and additional ingredients in solution, followed by removal of the processing solvents. The method and composition of this invention permit selectable loading of the drug into the dermal formulation and adjustment of the delivery rate of the drug from the composition through the dermis, while maintaining acceptable shear, tack, and peel adhesive properties.
  
  Patent expiration dates:
  
  
  • December 12, 2012
    
  
  
  
  • December 12, 2012
    
    ✓ 
    Drug product
  
  



• 
  Solubility parameter based drug delivery system and method for altering drug saturation concentration
  Patent 5,656,286
  Issued: August 12, 1997
  Inventor(s): Miranda; Jesus & Sablotsky; Steven
  Assignee(s): Noven Pharmaceuticals, Inc.
  A blend of at least two polymers, or at least one polymer and a soluble polyvinylpyrrolidone, in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin. According to the invention, soluble polyvinylpyrrolidone can be used to prevent crystallization of the drug, without affecting the rate of drug delivery from the pressure-sensitive adhesive composition.
  
  Patent expiration dates:
  
  
  • August 12, 2014
    
  
  
  
  • August 12, 2014
    
    ✓ 
    Drug product
  
  



• 
  Solubility parameter based drug delivery system and method for altering drug saturation concentration
  Patent 5,958,446
  Issued: September 28, 1999
  Inventor(s): Miranda; Jesus & Sablotsky; Steven
  Assignee(s): Noven Pharmaceuticals, Inc.
  The method of adjusting the saturation concentration of a drug in a transdermal composition for application to the dermis, which comprises mixing polymers having differing solubility parameters, so as to modulate the delivery of the drug. This results in the ability to achieve a predetermined permeation rate of the drug into and through the dermis. In one embodiment, a dermal composition of the present invention comprises a drug, an acrylate polymer, and a polysiloxane. The dermal compositions can be produced by a variety of methods known in the preparation of drug-containing adhesive preparations, including the mixing of the polymers, drug, and additional ingredients in solution, followed by removal of the processing solvents. The method and composition of this invention permit selectable loading of the drug into the dermal formulation and adjustment of the delivery rate of the drug from the composition through the dermis, while maintaining acceptable shear, tack, and peel adhesive properties.
  
  Patent expiration dates:
  
  
  • December 12, 2012
    
  
  
  
  • December 12, 2012
    
    ✓ 
    Drug product
  
  



• 
  Solubility parameter based drug delivery system and method for altering drug saturation concentration
  Patent 6,024,976
  Issued: February 15, 2000
  Inventor(s): Miranda; Jesus & Sablotsky; Steven
  Assignee(s): Noven Pharmaceuticals, Inc.
  A blend of at least two polymers, or at least one polymer and a soluble polyvinylpyrrolidone, in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin. According to the invention, soluble polyvinylpyrrolidone can be used to prevent crystallization of the drug, without affecting the rate of drug delivery from the pressure-sensitive adhesive composition.
  
  Patent expiration dates:
  
  
  • January 7, 2014
    
  
  
  
  • January 7, 2014
    
    ✓ 
    Drug product
  
  

See also...

• Vivelle-Dot Consumer Information (Cerner Multum)
• Estradiol Consumer Information (Drugs.com)
• Estradiol Consumer Information (Wolters Kluwer)
• Estradiol Acetate Consumer Information (Wolters Kluwer)
• Estradiol Cypionate Consumer Information (Wolters Kluwer)
• Estradiol Gel Consumer Information (Wolters Kluwer)
• Estradiol Gel Packets Consumer Information (Wolters Kluwer)
• Estradiol Patch Consumer Information (Wolters Kluwer)
• Estradiol Ring Consumer Information (Wolters Kluwer)
• Estradiol Spray Consumer Information (Wolters Kluwer)
• Estradiol Valerate Consumer Information (Wolters Kluwer)
• Estradiol Weekly Patch Consumer Information (Wolters Kluwer)
• Estring Ring Consumer Information (Wolters Kluwer)
• Estradiol injection Consumer Information (Cerner Multum)
• Estradiol oral Consumer Information (Cerner Multum)
• Estradiol topical for use on skin Consumer Information (Cerner Multum)
• Estradiol transdermal Consumer Information (Cerner Multum)
• Estradiol vaginal Consumer Information (Cerner Multum)
• Estradiol AHFS DI Monographs (ASHP)